Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine

In this article, Figure 4A was inadvertently replaced with that of an older draft, which was not suitable for publication, instead of the final confirmed proof. This error occurred due to circumstances beyond the control of the authors. Therefore, we would like to publish this Erratum to reflect this change. We apologize for the mistake.

Figure 4.

SK upregulates the expression of key enzymes involved in necroptosis. A: Expression of RIP1 and RIP3 in five pancreatic cancer cells. B: SK markedly upregulated RIP1 expression in PANC-1 cells whereas it had no significant effect on RIP3 expression. AsPC-1 cells showed the opposite pattern of RIP1 and RIP3 expression in response to SK treatment, with negative RIP1 protein expression in AsPC-1 cells treated with SK. C: Nec-1 or zVAD had no obvious effect on RIP3 expression. D: Silencing of RIP3 expression resulted in a marked decrease in the inhibition of cell proliferation by SK. Results represent the means ± SD from three independent experiments and *P<0.05, **P<0.01.

The corrected Figure 4 is as follows.